Table 2.
Intraocular pressure and medication use across different time points in patient groups
| Overall | POAG | NVG | PXG | PG | ACG | AG | PCG/JOAG | SOG | P value* | |
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 118) | (n = 37) | (n = 28) | (n = 15) | (n = 7) | (n = 8) | (n = 11) | (n = 8) | (n = 4) | ||
| Baseline IOP † | 38.8 ± 5.1 | 36.5 ± 4.8 | 39.4 ± 5.5 | 38.6 ± 4.7 | 38.3 ± 3.9 | 41.1 ± 3.2 | 41.9 ± 6.5 | 40.8 ± 3.8 | 40.2 ± 1.5 | 0.143 |
| IOP (Day 1) † | 18.0 ± 4.1 | 18.5 ± 3.1 | 16.6 ± 3.6 | 18.7 ± 4.1 | 16.3 ± 3.8 | 19.6 ± 4.2 | 19.5 ± 4.8 | 17.4 ± 7.3 | 19.0 ± 5.0 | 0.145 |
| IOP (Week 1) † | 18.1 ± 4.0 | 18.6 ± 2.8 | 17.0 ± 3.5 | 18.7 ± 3.6 | 16.9 ± 3.2 | 19.2 ± 4.9 | 19.0 ± 5.1 | 16.5 ± 7.5 | 18.5 ± 4.5 | 0.288 |
| IOP (Month 1) † | 18.2 ± 3.9 | 17.9 ± 3.0 | 17.5 ± 3.4 | 19.3 ± 3.9 | 16.9 ± 3.2 | 18.5 ± 4.1 | 19.8 ± 5.3 | 17.5 ± 7.3 | 19.5 ± 3.7 | 0.512 |
| IOP (Month 3) † | 18.5 ± 3.7 | 18.4 ± 3.0 | 17.8 ± 3.3 | 19.7 ± 3.5 | 16.7 ± 3.3 | 19.1 ± 3.7 | 19.7 ± 5.8 | 18.2 ± 5.3 | 19.5 ± 5.0 | 0.632 |
| IOP (Month 6) † | 18.8 ± 3.8 | 18.5 ± 3.2 | 18.4 ± 3.4 | 20.5 ± 3.4 | 17.9 ± 3.4 | 18.9 ± 4.3 | 19.6 ± 5.7 | 17.6 ± 5.4 | 18.2 ± 2.6 | 0.586 |
| IOP (Month 12) † | 19.5 ± 3.7 | 19.1 ± 2.9 | 19.0 ± 3.6 | 21.5 ± 3.5 | 18.0 ± 4.1 | 20.4 ± 3.8 | 20.1 ± 5.1 | 18.2 ± 4.4 | 19.8 ± 3.9 | 0.293 |
| P value ** | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | |
|
IOP reduction (%) Baseline to 12 Months † |
48.8 ± 11.5 | 46.5 ± 11.2 | 50.4 ± 12.6 | 43.7 ± 9.7 | 52.7 ± 10.6 | 50.6 ± 7.3 | 50.8 ± 14.8 | 55.1 ± 10.6 | 51.0 ± 8.6 | 0.203 |
|
Meeting the Success Criteria within 12 Months ‡ |
89 (75.4) | 30 (81.0) | 20 (71.4) | 11 (73.3) | 5 (71.4) | 6 (75.0) | 8 (72.7) | 6 (75.0) | 3 (75.0) | - |
| Baseline IOP † | 38.8 ± 5.1 | 36.5 ± 4.8 | 39.4 ± 5.5 | 38.6 ± 4.7 | 38.3 ± 3.9 | 41.1 ± 3.2 | 41.9 ± 6.5 | 40.8 ± 3.8 | 40.2 ± 1.5 | 0.143 |
| IOP (Month 12) † | 19.5 ± 3.7 | 19.1 ± 2.9 | 19.0 ± 3.6 | 21.5 ± 3.5 | 18.0 ± 4.1 | 20.4 ± 3.8 | 20.1 ± 5.1 | 18.2 ± 4.4 | 19.8 ± 3.9 | 0.293 |
| P value *** | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.022 | 0.014 | 0.004 | 0.014 | 0.025 | |
| Baseline medication † | 3.3 ± 0.7 | 3.3 ± 0.7 | 3.5 ± 0.6 | 2.9 ± 0.8 | 3.4 ± 0.8 | 3.5 ± 0.8 | 3.5 ± 0.7 | 3.1 ± 0.6 | 3.8 ± 0.5 | 0.271 |
| Medication (Month 12) † | 1.5 ± 1.0 | 1.6 ± 1.2 | 1.4 ± 0.8 | 1.4 ± 1.0 | 1.9 ± 1.1 | 1.6 ± 1.1 | 1.5 ± 0.8 | 1.6 ± 0.9 | 1.2 ± 1.3 | 0.934 |
| P value *** | < 0.001 | < 0.001 | < 0.001 | 0.002 | 0.039 | 0.013 | 0.003 | 0.021 | 0.029 | |
| Follow-up duration (months) † | 16.6 ± 3.0 | 16.4 ± 3.0 | 16.9 ± 2.8 | 16.1 ± 2.9 | 16.3 ± 3.8 | 17.1 ± 3.0 | 17.5 ± 3.0 | 16.6 ± 3.5 | 14.2 ± 2.6 | 0.588* |
POAG: Primary Open-Angle Glaucoma, NVG: Neovascular Glaucoma, PXG: Pseudoexfoliative Glaucoma, PG: Pigmentary Glaucoma, ACG: Angle-Closure Glaucoma, AG: Aphakic Glaucoma, PCG/JOAG: Congenital/Juvenile Glaucoma, SOG: Silicone Oil-Induced Glaucoma, IOP: Intraocular pressure
‡: n (%), †: Mean ± Standard Deviation
*. Kruskal Wallis-H test
**. Friedman test
***. Wilcoxon test